Compare Levi Strauss & Co. (LEVI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Pfizer Inc — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 21.7× Levi Strauss & Co.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Pfizer Inc for 158 Days on average.
| LEVI | PFE | |
|---|---|---|
Market Cap | $7.31B | $158.56B |
Volume | 13,683,095 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $29.02 |
52-Week Low | $17.92 | $23.67 |
Typical Hold Time | 70 Days | 158 Days |
Enterprise Value | $8.86B | $210.06B |
Dividend Yield | 3.36% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.53 and P/S of 1.12, while profitability remains solid with a net income margin of 8.83% and ROE of 25.76%.
Wall Street maintains a bullish stance with 15 buy ratings and a consensus price target of $29.00, implying significant upside. However, technical indicators show bearish momentum, and risks include competitive pressures and recent cybersecurity incidents. The stock's current price near recent support levels presents a potential entry point for value-oriented investors.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
